Endocrinology and metabolism clinics of North America

Drugs for Kidney Protection in Type 1 Diabetes: Sugar Transport Blockers, Incretin Hormone Boosters, and Finerenone

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Diabetes-related kidney disease (DKD) is a major complication of type 1 diabetes (T1D) and remains a leading cause of kidney failure.

  • DKD is associated with hyperglycemia-driven stress on the kidneys.
  • Maladaptive kidney blood flow and filtration processes may contribute to DKD progression.
  • Inflammation and scarring in the kidneys could be intensified by specific signaling pathways.
  • Emerging clinical evidence supports the potential benefits of kidney-protective therapies for T1D patients.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosure M.S. Hughes has consulted for Dexcom, Sequel Med Tech, and Sanofi and has received research support from Dexcom, United States, Insulet, United States, Sinocare, Medtronic, and Tandem. M.S. Hughes is partly supported by the National Institute of Diabetes and Digestive and Kidney Diseases, United States (NIDDK) (7K23DK138267). F.J. Pasquel reports research support to Emory University, United States from Dexcom and Insulet (device support), as well as from Ideal Medical Technologies, Tandem Diabetes Care, Medtronic, Sparrow Pharmaceuticals, and Novo Nordisk; consultant honorarium from Insulet (to Emory University); and in-kind transfer of value from Sanofi. F.J. Pasquel is partly supported by NIDDK (R01DK138366 and P30DK111024).
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief